Atea Pharmaceuticals (AVIR) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 33.3% versus a loss of 11.8%. Over five years, AVIR leads with a -51.4% price change compared with -69.0% for LRMR. Larimar Therapeutics is the larger company by market cap ($328.6 million vs $318.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | LRMR |
|---|---|---|
| Share price | $3.96 | $3.14 |
| Market cap | $318.00M | $328.55M |
| 1-day change | +0.76% | -2.48% |
| YTD return | +10.92% | -17.59% |
| 1-year return | +33.33% | -11.80% |
| 5-year return | -51.35% | -68.97% |
| EPS (TTM) | $-1.95 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-158.35M | $-165.67M |
| 52-week high | $6.45 | $6.42 |
| 52-week low | $2.96 | $1.92 |
| Distance from 52-week high | -38.60% | -51.09% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.27% | +352.23% |
| Average volume | 290.60K | 1.38M |
| Shares outstanding | 80.30M | 104.63M |
| Employees | 55 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed LRMR by 45.1 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
AVIR vs LRMR FAQ
Which is bigger, Atea Pharmaceuticals or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $328.55M compared with $318.00M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or LRMR?
AVIR returned +33.33% over the past 12 months, compared with -11.80% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.